Several posters have addressed the Sp value to the dose sales growth.
We know the following:
that the elevated SP of high 30s was based on 20% dose growth for the next 4/5 years.
the SP was hammered twice on reduction of estimates dose growth.
guidance is expect to be single digits.
the good work from SLC regarding analysis on SP based on growth.
So, the Q is, has anyone done a sensitively analysis of US dose growth (the only game on town) for the current 6 months?
My view is that the US growth over the current 6 months has the largest impact on the SP in the immediate future.
Would be good is anyone can post the analysis for US dose growth at the following rates:
3%
4%
6%
8%
10%
12%
15%
I would do this but am flat out with EOY crap currently.
Cheers
CAFA
- Forums
- ASX - By Stock
- dose sales - sensitivity analysis
Several posters have addressed the Sp value to the dose sales...
-
- There are more pages in this discussion • 52 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SRX (ASX) to my watchlist
(20min delay)
|
|||||
Last
17.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $75.62M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
SRX (ASX) Chart |
Day chart unavailable